华康生物医学(08622.HK)与春雷生物组合营 拓诊断男性生育能力市场业务
华康生物医学(08622.HK)公布,直接全资子公司华康香港後与春雷生物签订了谅解备忘录,内容有关可能於香港成立一间合资公司,其中华康香港占55%,春雷生物占45%。
华康香港在合资公司成立後六个月内,向合资公司出资不超过550万元以用作成立合资集团、研发活动和一般营运资金;春雷生物向合资公司授予若干春雷生物知识产权的独家许可和权利,以应用於合资公司在男性生育能力市场业务,及有关男性生育力领域的所有研发成果将实现和商业化,而该等许可和权利估值之总价值为不少於450万元。
合资公司以微流控技术和即时检验生物医学测试的使用及应用於诊断男性生育能力的相关研发;及商业化若干男性生育能力市场的微流控诊断产品。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.